Cargando…
Sorafenib induces variations of the DNA methylome in HA22T/VGH human hepatocellular carcinoma-derived cells
Sorafenib is currently used to treat advanced and/or unresectable hepatocellular carcinoma (HCC), but the increase of the median survival was only 3 months. Moreover, sorafenib has severe side effects and patients develop resistance quickly. Epigenetic alterations such as DNA methylation play a deci...
Autores principales: | Abeni, Edoardo, Salvi, Alessandro, Marchina, Eleonora, Traversa, Michele, Arici, Bruna, De Petro, Giuseppina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467784/ https://www.ncbi.nlm.nih.gov/pubmed/28560380 http://dx.doi.org/10.3892/ijo.2017.4019 |
Ejemplares similares
-
Effects of miR-193a and sorafenib on hepatocellular carcinoma cells
por: Salvi, Alessandro, et al.
Publicado: (2013) -
Biological Function of MicroRNA193a-3p in Health and Disease
por: Grossi, Ilaria, et al.
Publicado: (2017) -
Progesterone Increases Apoptosis and Inversely Decreases Autophagy in Human Hepatoma HA22T/VGH Cells Treated with Epirubicin
por: Chang, Wen-Tsan, et al.
Publicado: (2014) -
Arecoline induces HA22T/VGH hepatoma cells to undergo anoikis - involvement of STAT3 and RhoA activation
por: Cheng, Hsiao-Ling, et al.
Publicado: (2010) -
DNA methylation variations in familial female and male breast cancer
por: Abeni, Edoardo, et al.
Publicado: (2021)